XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash flows from operating activities:    
Net income (loss) $ (19,337,023) $ (10,866,209)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 2,730,660 2,270,621
Amortization of right-of-use assets 70,221 97,733
Stock-based compensation expense 1,886,841 2,045,664
Gain on sale of equipment (16,715) (15,793)
Change in fair value of warrant liabilities 96,172 (10,362,614)
Professional fees settled with equity instruments 143,530  
Changes in operating assets and liabilities    
Accounts receivable 5,556,577 (4,931,330)
Prepaid expenses 888,251 1,227,009
Operating lease right-of-use assets 394,862 (75,276)
Accounts payable (2,595,947) 1,025,751
Due to related party   (2,367)
Deferred grant income 1,627,421 (100,000)
Accrued expense and other current liabilities (3,117,538) (2,217,676)
Net cash used in operating activities (11,672,688) (21,904,487)
Cash flows from investing activities:    
Proceeds from the sale of equipment 44,450 76,390
Purchases of equipment (129,290) (2,048,660)
Net cash used in investing activities (84,840) (1,972,270)
Cash flows from financing activities:    
Payments of notes payable (772,665) (1,771,746)
Payments related to the Forward Share Purchase Agreement   (5,521,246)
Principal payments on finance leases (95,541) (120,053)
Proceeds from exercise of stock options 4,320 76,972
Net cash used in financing activities (863,886) (7,336,073)
Net decrease in cash and cash equivalents (12,621,414) (31,212,830)
Cash and cash equivalents    
Beginning of year 15,046,894 39,545,018
End of period 2,425,480 8,332,188
Supplemental disclosures:    
Cash paid for interest 179,222 $ 143,259
Supplemental information on non-cash investing and finance activities:    
Settlement of accrued liabilities through the issuance of common stock $ 1,500,000